Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDG-15400
- Development stage
- Phase 2
- Lead developer
- Edgewise Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**EDG-15400** is a novel investigational drug developed for the treatment of heart failure. It is being evaluated in first-in-human studies, specifically a Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, and food effects in healthy adults. The drug is administered orally, and clinical protocols include both single and multiple ascending doses as well as evaluation of different formulations (suspension versus tablet). The specific mechanism of action has not been publicly disclosed. The developer is Edgewise Therapeutics. There are currently no approved uses or broader information regarding its pharmacology or molecular target.
02
Targets
β-cardiac myosin S1 domain
Beyond the preview
Go deeper on EDG-15400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDG-15400.